Mantle Cell Lymphoma Treatment in Older Adults: Strategies
Revolutionizing Mantle Cell Lymphoma Treatment: A New Standard of care
Table of Contents
As of October 30, 2024, a significant shift in how mantle cell lymphoma (MCL) is treated has taken hold. the integration of Bruton tyrosine kinase (BTK) inhibitors – specifically ibrutinib and acalabrutinib – into first-line treatment regimens alongside immunochemotherapy now represents the new standard of care for patients. This change follows recent approvals for both drugs, extending treatment options too both those eligible for and ineligible for stem cell transplantation.
Treatment Strategies for Younger,Fit Patients
For younger and physically fit individuals diagnosed with MCL,a combination approach is proving highly effective. This involves administering ibrutinib in conjunction with R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone). This is strategically alternated with R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) as the initial, or induction, phase of treatment.
The Role of Transplantation and Maintenance
Following the induction phase, patients may be considered for autologous haematopoietic stem-cell transplantation (AHSCT). This procedure involves using the patient’s own stem cells to rebuild their immune system after high-dose chemotherapy.AHSCT is not mandatory, and the decision is made on a case-by-case basis, considering the patient’s overall health and response to initial treatment.
Regardless of whether transplantation is pursued, a period of time-limited maintenance therapy is often recommended. This ongoing treatment aims to sustain remission and prevent the lymphoma from returning.
BTK Inhibitors: A Targeted Approach
BTK inhibitors work by specifically targeting the Bruton tyrosine kinase enzyme, which plays a crucial role in the survival and growth of MCL cells. By blocking this enzyme,these drugs disrupt the signaling pathways that drive lymphoma progression. This targeted approach minimizes damage to healthy cells compared to conventional chemotherapy.
Looking Ahead
The approval and integration of BTK inhibitors represent a major advancement in the treatment of mantle cell lymphoma. Ongoing research continues to refine these treatment strategies and explore new combinations to further improve outcomes for patients. This evolving landscape offers renewed hope for individuals facing this challenging diagnosis.